bu 224 has been researched along with dexmedetomidine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dai, H; Ding, T; Yan, M; Yu, L; Zhang, F; Zhong, Y | 1 |
1 other study(ies) available for bu 224 and dexmedetomidine
Article | Year |
---|---|
Dexmedetomidine protects against oxygen-glucose deprivation-induced injury through the I2 imidazoline receptor-PI3K/AKT pathway in rat C6 glioma cells.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blotting, Western; Cell Survival; Dexmedetomidine; Glioma; Glucose; Hypoxia-Inducible Factor 1, alpha Subunit; Idazoxan; Imidazoles; Imidazoline Receptors; Oxygen; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Repressor Proteins; Transcription Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2012 |